India's Lupin Completes GAVIS Buy, Gains First U.S. Plant

Source: International Business Times

Mar 11, 2016

Mumbai-based Lupin has completed its acquisition of privately-held GAVIS Pharmaceuticals and Novel Laboratories (GAVIS).

New Jersey-based GAVIS brings with the sale its U.S.-based manufacturing and research organisation. The NJ manufacturing facility is Lupin's first manufacturing site in the United States.

The acquisition, which will broaden Lupin's pipeline in dermatology, controlled substance products and niche generic, also adds GAVIS' 62 abbreviated new drug applications (ANDAs) filings pending approval with the U.S. FDA and a pipeline of over 65 products under development.

Read the IBT article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments